Xeris Pharmaceuticals Operating Income Over Time
| XERS Stock | USD 6.12 0.62 9.20% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Xeris Pharmaceuticals Performance and Xeris Pharmaceuticals Correlation. Is there potential for Pharmaceuticals market expansion? Will Xeris introduce new products? Factors like these will boost the valuation of Xeris Pharmaceuticals. Anticipated expansion of Xeris directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Xeris Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.10) | Revenue Per Share | Quarterly Revenue Growth 0.371 | Return On Assets | Return On Equity |
Understanding Xeris Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Xeris's accounting equity. The concept of intrinsic value - what Xeris Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Xeris Pharmaceuticals' price substantially above or below its fundamental value.
Please note, there is a significant difference between Xeris Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xeris Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Xeris Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Xeris Pharmaceuticals and related stocks such as Immunocore Holdings, Sionna Therapeutics, and Abcellera Biologics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMCR | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (93.5 M) | (118.3 M) | (86.2 M) | (174.6 M) | (42.8 M) | (59.6 M) | (56.3 M) | (33.7 M) | (35.4 M) |
| SION | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (50.3 M) | (70.6 M) | (63.5 M) | (66.7 M) |
| ABCL | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (753 K) | (4.1 M) | 156 M | (4.1 M) | 216.5 M | (237.2 M) | (314.8 M) | (217.1 M) | (206.2 M) |
| BHVN | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (479.1 M) | (114.5 M) | (218.9 M) | (567.9 M) | (436.1 M) | (885.1 M) | (796.6 M) | (756.8 M) |
| VERA | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (48.1 M) | (34.4 M) | (90.9 M) | (102 M) | (167.2 M) | (150.5 M) | (142.9 M) |
| CLDX | (1.9 M) | (43.4 M) | (58.1 M) | (81.4 M) | (122.4 M) | (129.5 M) | (132.9 M) | (121.5 M) | (156.4 M) | (55 M) | (63.4 M) | (71.2 M) | (115.2 M) | (154.5 M) | (195.1 M) | (287.4 M) | (273 M) |
| JANX | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (4.8 M) | (32.9 M) | (67.1 M) | (73 M) | (98.8 M) | (89 M) | (84.5 M) |
| BCRX | (6.8 M) | (49.6 M) | (33.9 M) | (30.7 M) | (45.8 M) | (39.4 M) | (48.6 M) | (57.4 M) | (94.2 M) | (99.5 M) | (174.8 M) | (177.7 M) | (148.4 M) | (103.7 M) | (2.5 M) | 341 M | 358 M |
| MAZE | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (111 M) | (98.6 M) | 57.6 M | 66.2 M | 69.5 M |
| HRMY | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (41.4 M) | (145.9 M) | 17 M | 87.5 M | 120.2 M | 192 M | 190.8 M | 208.5 M | 218.9 M |
Xeris Pharmaceuticals and related stocks such as Immunocore Holdings, Sionna Therapeutics, and Abcellera Biologics Operating Income description
Operating Income is the amount of profit realized from Xeris Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Xeris Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Xeris Pharmaceuticals | XERS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1375 West Fulton |
| Exchange | NASDAQ Exchange |
USD 6.12
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.